Opportunity Alert – AC-160105-085 – CERECOR-03
Date Sourced: March 7, 2016
Category: Customer Opportunity
Status: Qualifying
Potential (High-Moderate-Low): Low
Add to SFA (Y/N): TBD
Client Action Required (Y/N): No
Opportunity:
Cerecor Inc. is a clinical-stage biopharmaceutical company with the goal of
becoming a leader in the development of innovative drugs focused on
neurological and psychiatric disorders. The company completed an IPO in
late 2015, raising $24M. Uli Hasksell became the new CEO in January 2016.
They currently have several drugs in Phase 2 and are looking toward Phase 3
trials.
Website: www.cerecor.com/
Summary of Activities/Tasks:
1. March 7, 1016 – Contacted Ron Marcus, Cerecor Chief Medical Officer with an
invite to the CleverCap Med Adherence CxO Briefing on March 22, 2016. No
response.
2. March 30, 2016 – Contacted Ron again after CTC in Boston. He followed-up
requesting a meeting to learn more about CleverCap. An online meeting for
April 7th at 11:30 AM was scheduled.
3. April 7, 2016 – Presented Ron Marcus. CMO and Eileen McNulty, Director of
Clinical Operations with a briefing on CleverCap.
Forward Statements and Guidance:
Ron Marcus is VERY focused on improving med adherence in Cerecor clinical
trials. Cerecor has a very small, very short study with 100% med adherence
where subjects are required to go to the site during the week; and take a
selfie of themselves taking the meds on weekends. They recognize that this
is only practical on extremely short 2-3 week studies.
Ron Marcus will circulate the CleverCap overview to internal Cerecor
stakeholders for additional input. The main challenge to immediate
CleverCap use is that the drugs they’ve licensed from Lily are in blister
packs. They do recognize the need to move to bottles for Phase 3 trials,
which are estimated to be 12 months away.
End.
Return to Listing
COMMENT FORM.
Comments